Summit Therapeutics Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert W. Duggan
- Full Time Employees
- 265
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 601 Brickell Key Drive Miami FL United States of America 02142
- IPO Date
- Mar 5, 2015
- CIK
- 0001599298
- Website
- smmttx.com
- Similar Companies
- Business
- Summit Therapeutics Inc. (Nasdaq: SMMT) is a biopharmaceutical company focused on the discovery, development, and commercialization of oncology therapies. The company develops ivonescimab, a novel bispecific antibody combining PD-1 blockade for immunotherapy with anti-VEGF-mediated anti-angiogenesis effects; ivonescimab is in global Phase III clinical trials, including HARMONi and HARMONi-3 for EGFR-mutated non-small cell lung cancer (NSCLC), HARMONi-6 for squamous NSCLC, HARMONi-7, and the recently announced HARMONi-GI3 for first-line metastatic colorectal cancer, with over 2,800 patients treated to date across trials. Summit holds exclusive licenses for ivonescimab in the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa, while partner Akeso, Inc. retains rights in other regions and conducts trials in China and Australia. Founded in 2003 and headquartered in Miami, Florida, with additional offices in Menlo Park, California, and Oxford, UK, the company targets solid tumors such as NSCLC and colorectal cancer. Recent developments include a $500 million private placement in October 2025 to fund operations and U.S. trial site openings for HARMONi-GI3 by year-end; collaborations with Pfizer to combine ivonescimab with antibody-drug conjugates and with Revolution Medicines for RAS(ON) inhibitors in NSCLC, pancreatic ductal adenocarcinoma, and colorectal cancer; positive HARMONi-6 top-line results in 2025 showing a 40% reduction in progression or death risk in squamous NSCLC; and completion of HARMONi enrollment with favorable survival trends in Western patients.
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet
First Look: U.S.-Iran Peace Deal Lifts Global Stocks, SpaceX Shines
Summit Therapeutics Announces Proposed Public Offering of Common Stock
Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
The Era of the One-Size-Fits-All Cancer Drug Is Ending
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy
Summit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress Transcript
What's Going On With Summit Therapeutics Stock On Monday?
Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON